ClinicalTrials.gg

Program

clofutriben

Also written as “SPI-62”, “ASP3662” and “SPI-62 dose”.

Its studies are mostly in Polymyalgia Rheumatica · Diabetes Mellitus, Type 2 · Cushing Syndrome · Obesity, led by 2 companies.

Furthest: phase 2, since Mar 23, 20229 company-led studies, 2 open or runningNext primary completion: Dec 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sparrow Pharmaceuticals72 open or runningphase 2since Mar 23, 2022Mar 23, 2022Dec 31, 2027phase 2 · NCT07296484
Astellas Pharma20 open or runningphase 2since Feb 21, 2015Jul 16, 2014none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 16, 2014First study: phase 1 study in Pharmacokinetics of ASP3662New to Astellas PharmaAstellas Pharma · NCT02194491 · 18 enrolled · United States
  2. Feb 21, 2015Phase 2 study in Painful Diabetic Peripheral Neuropathy (PDPN)Astellas Pharma · NCT02372578 · 115 enrolled · United States
  3. Mar 23, 2022Sparrow Pharmaceuticals's first study: phase 1 study in ObesityNew to Sparrow PharmaceuticalsSparrow Pharmaceuticals · NCT05409027 · 12 enrolled · United States
  4. Mar 23, 2022Phase 2 study in ACTH Syndrome, EctopicSparrow Pharmaceuticals · NCT05307328 · 26 enrolled · United States, Bulgaria, Romania
  5. Jun 23, 20222 phase 2 studiesSparrow Pharmaceuticals · NCT05436652, NCT05436639
  6. Feb 20, 2024Phase 1 study in Polymyalgia RheumaticaSparrow Pharmaceuticals · NCT06281236 · 1 enrolled · Germany
  7. Nov 6, 2025Phase 1 study in Moderate Renal ImpairmentSparrow Pharmaceuticals · NCT07227922 · 16 planned · United States
  8. Nov 30, 2025Phase 2 study in Diabetes Mellitus, Type 2Sparrow Pharmaceuticals · NCT07296484 · 1,500 planned · United States

Ahead

  1. Dec 31, 2027Primary completion: phase 2 study in Diabetes Mellitus, Type 2Sparrow Pharmaceuticals · NCT07296484

TargetBeta

“An orally bioavailable selective inhibitor of the enzyme 11beta-hydroxysteroid dehydrogenase type 1 (11b-HSD1; 11bHSD1; HSD11B1; HSD1; HSD-1), ”NCIt, by rule

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07296484Diabetes Mellitus, Type 2 · United States2RecruitingSparrow PharmaceuticalsDec 31, 20271,500
NCT07227922Moderate Renal Impairment · United States1RecruitingSparrow PharmaceuticalsApr 30, 202616
NCT06281236Polymyalgia Rheumatica · Germany1TerminatedSparrow PharmaceuticalsMar 25, 20251
NCT05436652Polymyalgia Rheumatica · Germany, Poland2CompletedSparrow PharmaceuticalsApr 25, 202566
NCT05436639Acth-Independent Macronodular Adrenal Hyperplasia · United States, Romania, United Kingdom2CompletedSparrow PharmaceuticalsDec 1, 202430
NCT05409027Obesity · United States1CompletedSparrow PharmaceuticalsMar 10, 202212
NCT05307328ACTH Syndrome, Ectopic · United States, Bulgaria, Romania2CompletedSparrow PharmaceuticalsAug 1, 202526
NCT02372578Painful Diabetic Peripheral Neuropathy (PDPN) · United States2TerminatedAstellas PharmaMay 20, 2016115
NCT02194491Pharmacokinetics of ASP3662 · United States1CompletedAstellas PharmaMay 201618

How it is read

Names in the registry

  • “SPI-62”, 4 entries
  • “ASP3662”, 2 entries
  • “clofutriben”, 1 entry
  • “SPI-62 dose”, 1 entry
  • “12mg clofutriben”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.